Criteria for Thrombectomy in Acute Ischemic Stroke

Primary Eligibility Criteria

The American Heart Association recommends mechanical thrombectomy for patients with acute ischemic stroke who are 18 years or older 1
Patients with a pre-stroke modified Rankin Scale (mRS) score of 0-1 are eligible for mechanical thrombectomy 1
Causative occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA) M1 segment is a criterion for mechanical thrombectomy 1
A National Institutes of Health Stroke Scale (NIHSS) score of 6 or higher is required for mechanical thrombectomy 1
An Alberta Stroke Program Early CT Score (ASPECTS) of 6 or higher is necessary for mechanical thrombectomy 1
Treatment should be initiated within 6 hours of symptom onset or last known well 1

Extended Time Window Criteria

The American Stroke Association recommends mechanical thrombectomy for patients within 6-16 hours of last known normal with large vessel occlusion (LVO) in the anterior circulation and who meet DAWN or DEFUSE 3 eligibility criteria 2, 3
For patients within 16-24 hours of last known normal, mechanical thrombectomy is reasonable if they have LVO in the anterior circulation and meet DAWN eligibility criteria 2, 3
A sizable mismatch between ischemic core and either clinical deficits or area of hypoperfusion is required for mechanical thrombectomy in the extended time window 1

Technical Considerations

The technical goal of mechanical thrombectomy should be reperfusion to a modified Thrombolysis in Cerebral Infarction (mTICI) grade 2b/3 1, 3
Stent retrievers are preferred over older devices like MERCI 4
Non-invasive angiography (e.g., CTA) is necessary for patients with clinically suspected LVO 1
Advanced imaging (CTP or DW-MRI, with or without MRI perfusion) is required for patients in the extended time window 1

Special Considerations

Mechanical thrombectomy can be considered for patients with occlusion or stenosis of the cervical ICA in addition to an intracranial LVO 1
Thrombectomy may be reasonable for carefully selected patients with causative occlusion of the MCA M2/M3 segments, anterior cerebral arteries, vertebral arteries, basilar artery, or posterior cerebral arteries within 6 hours 5
Eligible patients should receive IV thrombolysis even if mechanical thrombectomy is being considered 1
Evaluation of responses to IV thrombolysis should not delay catheter angiography for mechanical thrombectomy 1

Implementation Requirements

Treatment requires an experienced stroke center with immediate access to cerebral angiography and qualified interventionalists 6
Facilities should define criteria to credential individuals who can perform endovascular procedures 6
Patients should be transported rapidly to the closest available certified primary stroke center or comprehensive stroke center 4

Common Pitfalls and Caveats

Strict adherence to DAWN or DEFUSE-3 eligibility criteria is necessary for patient selection in the extended time window 3
The availability of mechanical thrombectomy should not preclude the administration of IV thrombolysis in eligible patients 1, 6
Observing patients after IV thrombolysis to assess for clinical response before pursuing endovascular therapy is not required and is not recommended 4

Evolution of Recommendations

Current guidelines from the American Heart Association strongly support the use of mechanical thrombectomy in appropriate patients 1, 2, 3

Contraindications and Considerations for Mechanical Thrombectomy

The American Heart Association suggests that high NIHSS scores are not contraindications; these patients may benefit most from intervention, with severe strokes (NIHSS >25-30) potentially benefiting from mechanical thrombectomy 7
Advanced age (>80 years) alone should not be an exclusion criterion, as elderly patients comprise the majority of stroke victims and may still benefit from mechanical thrombectomy 7

Technical Considerations

Inability to achieve safe vascular access, due to any condition making angiography technically impossible, represents a contraindication for mechanical thrombectomy 7

Guideline Recommendations

The American College of Chest Physicians (ACCP), as per the 2012 CHEST guidelines, initially suggested against mechanical thrombectomy (Grade 2C), but this recommendation is now obsolete 8

Mechanical Thrombectomy Selection Criteria for Acute Ischemic Stroke

Imaging Requirements

CT‑angiography must be performed to confirm occlusion of a large intracranial artery before proceeding to thrombectomy (International Stroke Guidelines) 9
In the early 0–6 hour window, CT‑perfusion imaging is not required to decide on thrombectomy (American College of Cardiology) 10
Multiphase CT‑angiography is routinely used to evaluate collateral circulation, which permits broader patient selection and avoids overly restrictive criteria (American College of Cardiology) 10

Quantitative Mismatch Thresholds (Extended Time Window)

A perfusion‑clinical mismatch ratio greater than 1.2 supports eligibility for thrombectomy (American College of Cardiology) 10
A mismatch volume exceeding 10 mL also qualifies patients for thrombectomy (American College of Cardiology) 10

Common Pitfalls and Safety Considerations

Critical error: Excluding patients with unknown symptom onset (e.g., wake‑up strokes) from thrombectomy because of strict late‑window criteria can deny treatment to individuals who are actually within the 6‑hour window (American College of Cardiology) 10
Bayesian decision‑making: When age, pre‑stroke functional status, and time from symptom onset are favorable, the relative importance of imaging findings (core volume) is reduced, decreasing uncertainty about treatment benefit (American College of Cardiology) 10

All statements reflect the evidence level reported in the cited sources; specific strength of recommendation was not provided.

Mechanical Thrombectomy in Patients ≥ 80 Years Old

Age‑Based Recommendation

The American Society of Neurointerventional Surgery (class IIa‑b) advises that age 80–90 years alone is not a contraindication to mechanical thrombectomy; the decision should be individualized for each patient. [11][12]13

Efficacy Evidence

A pooled analysis of five large trials (HERMES collaboration) demonstrated that, in patients ≥ 80 years, mechanical thrombectomy significantly improves outcomes compared with standard medical therapy (adjusted odds ratio 3.68; 95 % CI 1.95–6.92). Level of evidence: high‑quality meta‑analysis of randomized trials. 14
A separate meta‑analysis of Solitaire stent‑retriever studies (SWIFT‑PRIME, ESCAPE, EXTEND‑IA, REVASCAT) confirmed a strong benefit in the same age group (odds ratio 3.46; 95 % CI 1.58–7.60). Level of evidence: high‑quality meta‑analysis. 14
Although elderly patients have overall poorer outcomes than younger cohorts, they still achieve meaningful functional improvement (modified Rankin Scale) and reduced mortality after thrombectomy. Strength of evidence: consistent findings across multiple recent publications. [11][12]13

Procedural Timing & Imaging

Postponing catheter angiography to await the effect of intravenous thrombolysis worsens clinical outcomes; therefore, angiographic assessment should be performed without delay when thrombectomy is being considered. Evidence level: derived from pooled trial data. 14

Risk–Benefit Considerations

When selecting elderly candidates, clinicians must evaluate comorbid conditions and overall health status, but the overall benefit of thrombectomy outweighs the procedural risk given the high morbidity of untreated large‑vessel occlusion. Evidence level: supported by outcome data in the elderly subgroup. 14
Across multiple recent series, the net clinical advantage of thrombectomy in patients ≥ 80 years remains evident despite an approximate 15 % complication rate, because untreated occlusion carries a substantially higher risk of death and disability. Evidence level: corroborated by several contemporary cohort studies. [11][12]13

Management of Acute Middle Cerebral Artery Infarct with ASPECTS 0

Indications for Endovascular Thrombectomy

Endovascular thrombectomy is generally not recommended for patients with an ASPECTS 0 infarct because it represents a complete large‑core stroke with an extremely poor prognosis and a high risk of hemorrhagic transformation. 15
All landmark endovascular thrombectomy trials that provide Level A evidence excluded patients with very low ASPECTS scores, indicating that no high‑quality trial data support thrombectomy in this population. 16
The ESCAPE trial specifically required ASPECTS ≥ 6 for enrollment within 12 hours, further demonstrating that patients with ASPECTS 0 were not considered candidates for thrombectomy. 16
Recent large‑core trials (ANGEL‑ASPECT, SELECT2, TENSION, LASTE) set lower enrollment limits at ASPECTS 2–3 and did not include any ASPECTS 0 patients, underscoring the lack of trial evidence for benefit in this extreme core size. 15

Intravenous Alteplase Recommendations

The 2018 AHA/ASA guidelines state that the extent of hypoattenuation (ASPECTS) should not be used as a criterion to withhold IV alteplase in otherwise eligible patients; meta‑analyses showed no significant interaction between ASPECTS score and alteplase benefit. This recommendation is Class I, Level A. [17][18]
Consequently, within the 4.5‑hour window, IV alteplase may be administered to ASPECTS 0 patients provided no other contraindications exist, because the guideline does not exclude treatment based solely on ASPECTS. [17][18]

Hemorrhagic Risk Associated with Large Cores

Patients with large ischemic cores experience a substantially increased risk of reperfusion hemorrhage; pooled data from trials show an overall hemorrhage rate of 4.4 % with endovascular therapy versus 4.3 % in control groups. This reflects a modest absolute increase but highlights the heightened vulnerability of extensive infarcts. 19
In the specific context of an ASPECTS 0 infarct, the hemorrhagic risk is theoretically maximal because the entire MCA territory lacks salvageable tissue and is prone to transformation. 19

Procedural Risks and Clinical Pitfalls

Pursuing thrombectomy in ASPECTS 0 patients based on a “nothing to lose” rationale is discouraged, as procedural complications can exacerbate an already catastrophic situation without proven benefit. 19

All bullet points are derived from cited evidence and reflect current guideline and trial data.